October 6, 2017 10:37 AM EDT

AstraZeneca’s next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development rights to narcolepsy drug

John Carroll

Editor & Founder

→ Retraction Watch reports that one piece of the preclinical puzzle for the BTK drug acalabrutinib was fabricated by a researcher at Acerta. This …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca’s next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development rights to narcolepsy drug

John Carroll

Editor & Founder

Sign up to read this article for free.

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

As­traZeneca’s next big can­cer drug linked to fal­si­fied pre­clin­i­cal da­ta; Har­mo­ny rais­es $270M, nabs de­vel­op­ment rights to nar­colep­sy drug

John Carroll

Editor & Founder

Sign up to read this article for free.

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

AstraZeneca’s next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development rights to narcolepsy drug

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development